The goal of this clinical trial is to assess the performance and safety of the AQUABEAM Robotic System for the resection and removal of prostate tissue in patients experiencing lower urinary tract symptoms (LUTS) and are diagnosed with localized prostate cancer. Participants will go through baseline and follow up assessments up to 12 months.
Conditions: Benign Prostatic Hyperplasia, Localized Prostate Cancer
Eligibility Criteria
Inclusion Criteria
- International Prostate Symptom Score (IPSS) ≥ 8
- Gleason Grade Group 1-3
- Prostate-specific Antigen (PSA) ≤20ng/mL
- Cancer stage less than or equal to T2c
Exclusion Criteria
- Patients with previous surgical treatment of benign prostatic hyperplasia
- MRI evidence of extracapsular extension of cancer
- Any severe illness that would prevent complete study participation or confound study results
Eligibility criteria are kept as the original English records from ClinicalTrials.gov; actual eligibility is determined by the research team's formal assessment and the informed consent form. Source: ClinicalTrials.gov, updated automatically every two weeks. Last synced: 2026年10月8日.